Document Detail

Steroids for the prevention of restenosis in bare-metal stents - a systematic review and meta-analysis.
MedLine Citation:
PMID:  22388299     Owner:  NLM     Status:  In-Data-Review    
INTRODUCTION: Stent restenosis remains a common complication of bare-metal stent (BMS) implantation. Even in the drug-eluting stent (DES) era, there remains a significant proportion of patients who may not be eligible for DES due to inability to comply with prolonged dual antiplatelet therapy. We reviewed the validity of empirical evidence that periprocedural treatment with steroids at the time of insertion of a BMS may delay restenosis and provide benefit through reductions in adverse clinical events.
METHODS: We searched the PubMed, EMBASE and Cochrane Central Register of Controlled Trials databases for randomized controlled trials conducted between 1990 and 2011 that assessed the impact of systemic steroid administration within 72 hours to 7 days of angioplasty alone and BMS placement. The comparator included standard medical therapy and/or placebo. Outcomes assessed were: (1) rates of restenosis at the end of at least 6 months of follow-up; (2) rates of target vessel revascularization; and (3) risk of all-cause mortality. The methodological quality of the studies was assessed, as was publication bias. Relative risk of restenosis, revascularization, and rates of in-hospital mortality for treatment and control groups were compared using a random effects model (Mantel- Haenszel).
RESULTS: We identified 5 studies that met inclusion criteria. No significant reduction in restenosis rates was observed after angioplasty alone with steroids. However, with BMS, significant reductions in restenosis rates (relative risk [RR], 0.60; 95% confidence interval [CI], 0.37-0.97; P=.04), and target vessel revascularization rates (RR, 0.56; 95% CI, 0.34-0.92; P=.02) were observed in the steroid-treated group. A 28% mortality reduction was observed with steroid treatment with BMS placement, but was not statistically significant.
CONCLUSION: Periprocedural steroid administration during BMS implantation may reduce rates of restenosis and target vessel revascularization, without adverse clinical effects attributable to steroid use.
Partha Sardar; Saurav Chatterjee; Debabrata Mukherjee; Kirk N Garratt
Related Documents :
22622999 - Five-year outcomes of cypher™ coronary stent: report from j-pms study.
8817139 - Early and long-term results for correction of total anomalous pulmonary venous drainage...
23432209 - A prospective randomized toxicity study to compare reduced-intensity and myeloablative ...
1835279 - Prognostic features of children with idiopathic dilated cardiomyopathy.
12171829 - Dobutamine gated blood pool scintigraphy predicts the improvement of cardiac sympatheti...
20026539 - Incidence and impact of cardiac cachexia in valvular surgery.
58259 - A five-year follow-up of lord's dilatation for haemorrhoids.
3332119 - A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host ...
22924039 - Significance of the intraoperative methylene blue test for postoperative evaluation of ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of invasive cardiology     Volume:  24     ISSN:  1557-2501     ISO Abbreviation:  J Invasive Cardiol     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-03-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8917477     Medline TA:  J Invasive Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  98-103     Citation Subset:  IM    
Maimonides Medical Center, 864 49th Street Apt. C11, Brooklyn, NY 11220 USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Different spectrum of vascular complications after angio-seal deployment or manual compression.
Next Document:  Gender-Based Analysis of the 3-Year Outcome of Bioactive Stents Versus Paclitaxel-Eluting Stents in ...